Literature DB >> 9718384

Erythropoietin for end-stage renal disease.

J W Adamson, J W Eschbach.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9718384     DOI: 10.1056/NEJM199808273390910

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells.

Authors:  Emilia Stellacci; Antonella Di Noia; Angela Di Baldassarre; Giovanni Migliaccio; Angela Battistini; Anna Rita Migliaccio
Journal:  Exp Hematol       Date:  2009-05       Impact factor: 3.084

Review 2.  Markers of iron status in chronic kidney disease.

Authors:  Adam E Gaweda
Journal:  Hemodial Int       Date:  2017-03-22       Impact factor: 1.812

3.  Incorporating short-term outcome information to predict long-term survival with discrete markers.

Authors:  Layla Parast; Su-Chun Cheng; Tianxi Cai
Journal:  Biom J       Date:  2011-02-21       Impact factor: 2.207

4.  Intravenous iron therapy: how far have we come?

Authors:  Rodolfo Delfini Cançado; Manuel Muñoz
Journal:  Rev Bras Hematol Hemoter       Date:  2011

5.  The role of glucocorticoid receptor (GR) polymorphisms in human erythropoiesis.

Authors:  Lilian Varricchio; Anna Rita Migliaccio
Journal:  Am J Blood Res       Date:  2014-12-15

6.  Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels.

Authors:  Katherine A Cappell; Sanatan Shreay; Zhun Cao; Helen V Varker; Carly J Paoli; Matthew Gitlin
Journal:  BMC Nephrol       Date:  2014-07-11       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.